**Author details**

Chiranjeev Sharma and Satish Kumar Awasthi\*

\*Address all correspondence to: skawasthi@chemistry.du.ac.in

Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi, India

## **References**


a comparative study with human and rodent parasites. *PLOS Medicine* 2012; 9(2): e1001169/1–e1001169/14.

[11] World Health Organization. Guidelines for the Treatment of Malaria. Second edition. March 2010.

**Acknowledgements**

56 An Overview of Tropical Diseases

**Author details**

**References**

University of Delhi, Delhi-110007, India.

Chiranjeev Sharma and Satish Kumar Awasthi\*

\*Address all correspondence to: skawasthi@chemistry.du.ac.in

ia\_report\_2014/en/ (accessed 21.03.2015).

mosquitoes. *Science* 2015; 347(6217), 1258522.

of positive selection. *Parasitology* 2015; 142(S1): S98–S107.

2012; 111(1), 1–6.

2013,443-459.

228(4703), 1049–1055.

CS is thankful to UGC, New Delhi, for SRF. SKA acknowledges the financial support from the

Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi, India

[1] Poinar G. Plasmodium dominicana n. sp. (Plasmodiidae: Haemospororida) from Ter‐

[2] World Malaria Report 2014, http://www.who.int/malaria/publications/world\_malar‐

[3] Eve WE, Basu S, Hanson K. Is malaria a disease of poverty? A review of the litera‐

[4] Greenwood D. Conflicts of interest: the genesis of synthetic antimalarial agents in

[5] Krafts K, Hempelmann E, Skorska-Stania A. From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy. *Parasitology Research*

[6] Kayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. *Science* 1985;

[7] Neafsey DE, et al. Highly evolvable malaria vectors: the genomes of 16 *Anopheles*

[8] Chang HH, Hartl DL. Recurrent bottlenecks in the malaria life cycle obscure signals

[9] Neupane CS, Awasthi SK. In: Synthetic Quinolones: Emerging Antimalarial Agents. A. Pandey (eds.), Antibacterial activity in natural and synthetic compounds.

[10] Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. The activities of current antimalarial drugs on the life cycle stages of plasmodium:

tiary Dominican amber. *Systematic Parasitology* 2005; 61(1), 47–52

ture. *Tropical Medicine and International Health* 2005; 10(10), 1047–1059.

peace and war. *Journal of Antimicrobial Chemotherapy* 1995; 36(5), 857–872.


[39] La-Venia A, Mata EG, Mischne MP. Photoinduced oxygen capture on immobilized dienone systems. First solid-phase synthesis of trioxane scaffolds. *Journal of Combina‐ torial Chemistry* 2008; 10(4), 504–506.

[26] Graves PM, Levine MM. Battling Malaria: Strengthening the U.S. Military Malaria

[27] Olotu A, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria ex‐

[28] Crowther GJ, et al. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. *Molecular and Biochemical Parasitology* 2011;

[29] Guantai E, Chibale K. How can natural products serve as a viable source of lead com‐ pounds for the development of new/novel anti-malarials? *Malaria Journal* 2011,

[30] Department of International Development. Medicines For Malaria Venture (MMV) 2005–2010. MMV in natural products: harnessing the power of nature in malaria drug discovery. 2009, http://r4d.dfid.gov.uk/PDF/Outputs/MMV/MMV\_in\_Natu‐

[31] Nogueira CR, Lopes LMX. Antiplasmodial natural products. *Molecules* 2011; 16,

[32] Agarwal D, Sharma M, Dixit SK, Dutta RK, Singh AK, Gupta RD, Awasthi SK. In vi‐ tro synergistic effect of fluoroquinolone analogs in combination with artemisinin against *Plasmodium falciparum*; their antiplasmodial action in rodent malaria model.

[33] Dixit SK, Yadav N, Kumar S, Good L, Awasthi SK. Synthesis and antibacterial activi‐ ty of fluoroquinoone analogs. *Medicinal Chemistry Research* 2014; 23(12), 5237–5249.

[34] Yadav N, Sharma C, Awasthi SK. Diversifications in the synthesis of antimalarial tri‐

[35] Singh C, Malik H, Puri SK. Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxas‐ piro[5.5]undecanes against multi-drug-resistant *Plasmodium yoelii nigeriensis* in mice.

[36] Singh C, Gupta N, Puri SK. Geraniol-derived 1,2,4-trioxanes with potent in-vivo anti‐ malarial activity. *Bioorganic and Medicinal Chemistry Letters* 2003; 13(20), 3447–3450.

[37] Sabbani S, Stocks PA, Ellis GL, Davies J, Hedenstrom E, Ward SA, O'Neill PM. Piper‐ idine dispiro-1,2,4-trioxane analogues. *Bioorganic and Medicinal Chemistry Letters* 2008;

[38] Rubush DM, Morges MA, Rose BJ, Thamm DH, Rovis T. An asymmetric synthesis of 1,2,4-trioxane anticancer agents via desymmetrization of peroxyquinols through a Brønsted acid catalysis cascade. *Journal of American Chemical Society* 2012; 134(33),

oxane and tetraxoane analogs. *RSC Advances* 2014; 4, 5469–5498.

*Journal of Medicinal Chemistry* 2006; 49(9), 2794–2803.

posure. *New England Journal of Medicine* 2013; 368(12), 1111–1120.

Vaccine Program. 2006, pp. 26–33.

ral\_Products.pdf (accessed 21.03.2015)

*Malaria Journal* 2015; 14(1), 48.

18(21), 5804–5808.

13554−13557.

175(1), 21–29.

58 An Overview of Tropical Diseases

10(Suppl 1):S2.

2146–2190.

